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Abstract The experiments investigated the applicability of
two established criteria for arrhythmogenicity in Scn5a+/Δ
and Scn5a+/− murine hearts modelling the congenital long
QT syndrome type 3 (LQT3) and the Brugada syndrome
(BrS). Monophasic action potentials (APs) recorded during
extrasystolic stimulation procedures from Langendorff-
perfused control hearts and hearts treated with flecainide
(1 μM) or quinidine (1 or 10 μM) demonstrated that both
agents were pro-arrhythmic in wild-type (WT) hearts,
quinidine was pro-arrhythmic in Scn5a+/Δ hearts, and that
flecainide was pro-arrhythmic whereas quinidine was anti-
arrhythmic in Scn5a+/− hearts, confirming clinical find-
ings. Statistical analysis confirmed a quadratic relationship
between epicardial and endocardial AP durations (APDs) in
WT control hearts. However, comparisons between plots of
epicardial against endocardial APDs and this reference
curve failed to correlate with arrhythmogenicity. Restitution
curves, relating APD to diastolic interval (DI), were then
constructed for the first time in a murine system and mono-
exponential growth functions fitted to these curves. Signif-
icant (P<0.05) alterations in the DI at which slopes
equalled unity, an established indicator of arrhythmogenic-
ity, now successfully predicted the presence or absence of
arrhythmogenicity in all cases. We thus associate changes
in the slopes of restitution curves with arrhythmogenicity in
models of LQT3 and BrS.
Keywords Action potential.Arrhythmia.Heart.
Heart rate.Heartexcitation.Venticularmuscle.Ventricle
Introduction
Mutations in the SCN5a gene encoding the α-subunit of the
cardiac voltage-gated Na
+ channel are well established to
underlie hereditary arrhythmic syndromes which may result
in sudden cardiac death. On the one hand, gain-of-function
mutations which increase inward depolarising currents and
consequently prolong the ventricular action potential are
associated with arrhythmogenicity in the congenital long
QT syndrome type 3 (LQT3) [23]. On the other hand, loss-
of-function mutations which decrease such currents are
associated with arrhythmogenicity in the Brugada syn-
drome (BrS) [1]. In this case, spatial heterogeneities in the
degree of shortening of the ventricular action potential
result in characteristic electrocardiographic changes, name-
ly a partial right bundle branch block pattern with ST
segment elevation in the right precordial leads [2].
Despite the similar clinical outcomes of LQT3 and BrS,
class 1A and 1C, anti-arrhythmic agents, exemplified by
quinidine and flecainide respectively, exert contrasting
effects on arrhythmogenicity in these two syndromes [31].
Thus in LQT3, quinidine is pro-arrhythmic [33]a n d
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quinidine is anti-arrhythmic [24], while flecainide is pro-
arrhythmic [7] and used to unmask the arrhythmic
phenotype in asymptomatic patients. These contrasts are
precisely reflected in results from our murine models of
LQT3 [39] and BrS [38], emphasizing the translatability of
results obtained from such systems. Furthermore, both
quinidine and flecainide are known to have the potential
for pro-arrhythmic effects [12, 30].
These similarities and differences have parallels in the
physiological changes thought to underlie arrhythmogenic-
i t yi nL Q T 3a n dB r S .T h u sc i r c u s - t y p er e - e n t r y[ 2],
requiring both an initiating trigger and a re-entrant
substrate, has been implicated in arrhythmogenicity in both
these conditions. Of these requirements, both conditions are
associated with triggering extrasystoles [3]. In LQT3, these
are initiated by early after-depolarizations attributable to
action potential prolongation [42], while in BrS they are
initiated by phase 2 re-entry [20, 46]. Furthermore, in both
LQT3 and BrS, arrhythmia occurs against a re-entrant
substrate [3]. In LQT3 this is provided by increased
transmural dispersion of repolarization [13, 27, 42]. While
increased transmural dispersion of repolarization has also
been demonstrated in some studies on BrS [3], increased
epicardial dispersion of repolarization [2] and slowed
conduction [29] are also implicated. Thus studies in murine
hearts have associated alterations in transmural dispersion
of repolarization, reflected in relationships between epicar-
dial and endocardial action potential durations, with
arrhythmogenicity in models of LQT3 but failed to do so
in models of BrS [21, 33, 38, 39, 42].
Arrhythmogenicity has often been associated with
increases in the slopes of restitution curves, plotting action
potential duration against the preceding diastolic interval, to
greater than unity [14, 17–19, 28, 40]. Possible mechanisms
that might underlie this association have been discussed in
detail on a number of occasions [11, 25, 43, 44].
Furthermore, decreases in the slopes of such curves are
associated with the anti-arrhythmic effects of several
clinically important agents including amiodarone, bretylium
and procainamide [11, 26, 32]. Such associations have
previously been demonstrated in a pharmacological model
of LQT2 [45] but has not been assessed in LQT3 or in BrS.
The present study compares an analysis examining
transmural dispersion of repolarization, assessed by com-
paring epicardial and endocardial action potential durations
obtained over a range of heart rates and previously
established to predict arrhythmogenicity in hypokalaemic
Langendorff-perfused murine hearts [34], with another
examining effects on restitution curve parameters. This
represents the first occasion on which restitution curves
have been constructed in a murine system, in relation to
BrS or LQT3, or indeed in any genetic model of an
hereditary arrhythmic syndrome. To this end, the mono-
phasic action potential (MAP) technique and an established
Langendorff-perfused system [15, 34–36] are used to study
genetically modified mice modelling LQT3 (Scn5a+/Δ)
[13] and BrS (Scn5a+/−)[ 29] before and after exposure to
quinidine and flecainide. We proceed to demonstrate that
while the former criterion fails, the latter produces
predictions in full agreement with the arrhythmogenic
findings in every case and thus suggest that alterations in
the slopes of restitution curves are associated with
arrhythmogenicity in both LQT3 and BrS.
Materials and methods
Experimental animals
Wild-type (WT), Scn5a+/Δ and Scn5a+/− 129 Sv mice
aged 3–6 months were housed at 21±1°C with 12 h light/
dark cycles. They were fed sterile chow (RM3 Maintenance
Diet, SDS, Witham, Essex, UK) and had free access to
water. All procedures complied with the UK Animals
(Scientific Procedures) Act 1986.
Solutions
Solutions were based on bicarbonate-buffered Krebs-
Henseleit solution (119 mM NaCl, 25 mM NaHCO3,
4 mM KCl, 1.2 mM KH2PO4, 1 mM MgCl2, 1.8 mM
CaCl2,1 0m Mg l u c o s ea n d2m MN a - p y r u v a t e ;p H
adjusted to 7.4) and were bubbled with 95% O2/5% CO2
(British Oxygen Company, Manchester, U.K). Drug-
containing solutions were prepared by adding flecainide
(Sigma-Aldrich, Poole, UK) to final concentration of 1 μM
and quinidine (Sigma-Aldrich, Poole, UK) to final concen-
trations of 1 and 10 μM: these concentrations were chosen
to reflect clinically therapeutic values (effective free and
total plasma concentrations of 0.79 and 1.48 μM, respec-
tively, for flecainide and 0.74 and 7.9 μM, respectively, for
quinidine) [9].
Preparation
A Langendorff-perfusion protocol previously adapted for
murine hearts [4] was used. Briefly, mice were killed by
cervical dislocation [Schedule 1: UK Animals (Scientific
Procedures) Act 1986] before hearts were quickly excised
and placed in ice-cold bicarbonate-buffered Krebs-
Henseleit solution. Short sections of aorta were cannulated
under the surface of the solution and attached to a custom-
made 21-gauge cannula filled using an aneurysm clip
(Harvard Apparatus, Edenbridge, Kent, UK), within 90 s
of excision. Fresh Krebs-Henseleit solution was passed
638 Pflugers Arch - Eur J Physiol (2008) 455:637–651through 200- and 5-μm filters (Millipore, Watford, UK) and
warmed to 37°C using a water jacket and circulator (Techne
model C-85A, Cambridge, UK). This solution was then
used for constant-flow retrograde perfusion, thereby cir-
cumventing any changes in coronary vascular resistance
and therefore flow that might otherwise result from the
effects of the drugs studied [10], at 2–2.5 ml/min, driven by
a peristaltic pump (Watson-Marlow Bredel model 505S,
Falmouth, Cornwall, UK). Hearts were regarded as suitable
for experimentation if they regained a healthy pink colour
and began to contract spontaneously on re-warming.
Electrophysiological measurements
An epicardial MAP electrode (Hugo Sachs, Harvard
Apparatus, UK) was placed against the basal left ventricular
epicardium. A custom-made endocardial MAP electrode
consisting of two twisted strands of high-purity Teflon-
coated silver wire of 0.25 mm diameter (Advent Research
Materials, UK) was manufactured. A small access window
was created in the interventricular septum to allow access to
the left ventricular endocardium [8]. The Teflon coating
was removed from the distal 1 mm of the electrode; this
was then galvanically chlorided to eliminate DC offset,
inserted and placed against the septal endocardial surface.
MAPs were amplified, band-pass filtered (0.5 Hz to 1 kHz:
Gould 2400S, Gould-Nicolet Technologies, Ilford, Essex,
UK) and digitised at a sampling frequency of 5 kHz
(micro1401, Cambridge Electronic Design, Cambridge,
UK). Analysis of MAPs was performed using Spike II
(Cambridge Electronic Design, Cambridge, UK).
Experimental protocol
A bipolar platinum stimulating electrode (1 mm inter-pole
spacing) was placed on the basal surface of the right
ventricular epicardium. Square-wave stimuli (Grass S48
stimulator, Grass-Telefactor, Slough, UK) of 2 ms duration
and amplitudes of twice the excitation threshold were
initially applied to hearts at a constant baseline cycle length
(BCL) of 125 ms until MAPs showed stable baselines,
rapid upstroke phases that reached consistent amplitudes
and smooth repolarization phases [16] and for at least
10 min. Before subsequent recordings were made, hearts
were then exposed to test solutions for 20 min while
stimulation was continued.
In initial experiments, MAPs were recorded during
regular stimulation at a BCL of 125 ms. Arrhythmogenicity
was then assessed both during regular stimulation and using
an extrasystolic stimulation protocol [37] previously adap-
ted for the study of arrhythmogenesis in murine hearts
incorporating the Scn5a+/Δ and Scn5a+/− mutations [13,
38] and described below. Hearts were then subjected to an
adapted dynamic pacing protocol [17] explained in detail
below, and the data obtained used to construct restitution
curves.
Data analysis
All data are presented as means ± standard errors of the
means and include the number of hearts studied. Compar-
isons between data sets used analysis of variance (signif-
icance threshold set at P≤0.05). Curve fitting of particular
functions to data sets used a Levenberg-Marquardt algo-
rithm (OriginPro 7.5, OriginLab, MA, USA).
Results
The experiments made direct measurements of MAPs from
intact Langendorff-perfused murine hearts. They compared
the extents to which relationships between epicardial and
endocardial action potential durations and the slopes of
restitution curves are associated with arrhythmogenicity in
genetic models of the congenital LQT3 (Scn5a+/Δ) and of
the BrS (Scn5a+/−), and in wild-type (WT) controls. They
began by successfully demonstrating that these experimen-
tal models recapitulated arrhythmic phenotypes observed
clinically as well as confirming the anticipated effects of
treatment with clinically-relevant [6] concentrations of
flecainide (1 μM) and quinidine (1 or 10 μM). Hearts were
exposed to solutions for 20 min while stimulated at a
constant BCL of 125 ms before recording was commenced.
Arrhythmogenicity in WT, Scn5a+/Δ and Scn5a+/− hearts
subject to both regular and extrasystolic stimulation
recapitulates clinical observations
Figures 1 and 2 show results obtained from WT (Figs. 1a,
2a), Scn5a+/Δ (Figs. 1b, 2b) and Scn5a+/− (Figs. 1c, 2c)
hearts treated with control solution (A) and with solutions
containing 1 μM flecainide (B), 1 μM quinidine (C) and
10 μM quinidine (D). Figure 1 illustrates MAP waveforms
recorded from the epicardia of hearts during the extra-
systolic stimulation procedure showing arrhythmic wave-
forms in situations where arrhythmic activity was observed
in >50% of cases; Fig. 2 quantifies the incidence of such
arrhythmic activity both during regular stimulation (i) and
during the extrasystolic stimulation procedure (ii).
The frequencies of arrhythmic phenomena in hearts
subjected to regular stimulation at a BCL of 125 ms were
relatively low irrespective of the genetic or pharmacological
conditions but were nevertheless consistent with clinical
expectations. First, zero out of seven WT hearts (~0%,
Fig. 2a, i) exposed to control solution (A) demonstrated
arrhythmic activity, while treatment with flecainide (B) led
Pflugers Arch - Eur J Physiol (2008) 455:637–651 639to arrhythmic activity in only one out of six (~17%) cases.
Furthermore, such hearts never showed arrhythmic activity
during treatment with 1 μM quinidine (C, zero out of six
hearts, ~0%) and again did so in only one out of six cases
(~17%) with 10 μM quinidine (D). Secondly, arrhythmic
activity did occur in one out of six (~17%) Scn5a+/Δ
hearts (Fig. 2b) treated with control solution (A) and was
absent in all cases (zero out of six hearts, ~0%) during
treatment with flecainide (B). Arrhythmic activity was not
observed (zero out of four hearts, ~0%) during treatment
with 1 μM quinidine (C) but did occur in one out of five
hearts (~20%) exposed to 10 μM quinidine (D). Thirdly,
two out of nine Scn5a+/− hearts (~22%, Fig. 2c) exhibited
arrhythmic activity during exposure to control solution (A).
Such arrhythmic activity was also observed in one out of
five hearts (~20%) treated with flecainide (B). Arrhythmic
activity was then absent after treatment with either 1 μM
(C) or 10 μM (D) quinidine (zero out of five, 0%, and zero
out of six, 0%, hearts, respectively).
In contrast, extrasystolic stimulation (Figs. 1 and 2, ii)
revealed clearer trends in arrhythmogenicity in full agree-
ment with clinical expectations. First, while zero out of
seven WT hearts (0%, Fig. 2a, ii) exposed to control solution
(A) exhibited arrhythmic activity, treatment with flecainide
(B) increased the incidence of such events to two out of six
hearts (~33%). Furthermore, exposure to 1 μM quinidine
(C) resulted in arrhythmic activity in four out of eight hearts
(~50%), while exposure to 10 μM quinidine (D) resulted in
arrhythmic activity in three out of six hearts (~50%).
Secondly, one out of five Scn5a+/Δ hearts (~20%, Fig. 2b,
ii) demonstrated arrhythmic activity during exposure to
either control solution (A) or flecainide (B). However,
exposure to quinidine resulted in arrhythmic activity in three
out of five hearts (~60%) at 1 μM (C) and four out of four
hearts (~100%) at 10 μM( D ) .T h i r d l y ,Scn5a+/− hearts
(Fig. 2c, ii) demonstrated such arrhythmic activity in three
out of nine cases (~33%) during treatment with control
solution (A) but in five out of six cases (~83%) during
Regular (S1) stimulus
Extrasystolic (S2) stimulus
MAP 
V
250 ms
a WT b Scn5a +/∆  
A
Control
B
Flecainide
C
1 µM quinidine
D
10 µM quinidine
c Scn5a +/-
Fig. 1 Arrhythmic activity resulting from extrasystolic stimulation.
Epicardial monophasic action potential (MAP) recordings illustrat-
ing the result of the application of extrasystolic stimuli to WT (a),
Scn5a+/Δ (b) and Scn5a+/− (c) hearts treated with control solution
(A) and with solutions containing 1 μM flecainide (B), 1 μM quinidine
(C) and 10 μM quinidine (D). Traces show arrhythmic activity where
this was observed in ≥50% of cases
640 Pflugers Arch - Eur J Physiol (2008) 455:637–651treatment with flecainide (B). Furthermore, arrhythmic
activity was observed in only one out of six such hearts
(~17%) during treatment with 1 μM quinidine (C) and in zero
out of six hearts during exposure to 10 μM quinidine (D).
Graphical analyses of arrhythmogenic tendency
In an effort to explore the possible basis for these
arrhythmic phenomena, subsequent experiments made
systematic measurements of epicardial and endocardial
action potential durations (at 90% repolarization, APD90s)
during a dynamic pacing protocol [17]. This consisted of
cycles each comprising 100 stimuli, initially delivered at a
BCL of 175 ms. BCL was then decremented in 50-ms steps
with each subsequent cycle until a reproducible sequence of
consistently shaped MAP waveforms was no longer
obtained. Steady states were consistently reached within
the first 50 responses, and therefore mean values of APD90
were obtained from the final 50 action potentials in each
cycle. This approach provided data that could be used to
evaluate over the full range of BCLs the relationship
between arrhythmogenicity and two possible electrophysi-
ological properties. Thus it was possible first to evaluate
transmural repolarization gradients and secondly to evaluate
slopes of restitution curves relating APD90 to the preceding
DI, given by BCL minus APD90 [17, 25, 28, 43].
Relationships between epicardial and endocardial action
potential durations are not consistently associated
with either the presence or absence of arrhythmogenicity
Alterations in relationship between epicardial and endocar-
dial APD90 determined at a single BCL has previously been
associated with arrhythmogenicity in hearts obtained from
our Scn5a+/Δ mice [42]. The present study now extends
this analysis from a single BCL to a range of BCLs and
applies it to Scn5a+/− hearts for the first time, plotting
endocardial APD90 on the abscissa and epicardial APD90
on the ordinate over the full range of BCLs investigated
(triangles, Fig. 3). Such plots have previously been used to
assess arrhythmogenicity in hypokalaemic WT murine
hearts [34] and provided possible criteria for arrhythmoge-
Fig. 2 Incidences of arrhythmic activity in WT, Scn5a+/Δ and
Scn5a+/− hearts subjected to the extrasystolic stimulation proce-
dure. Percentage of WT (a), Scn5a+/Δ (b)a n dScn5a+/− (c) hearts
demonstrating arrhythmic activity during regular stimulation (i) and
during the extrasystolic stimulation procedure (ii). In both these
cases, MAPs were obtained during treatment with control solution
(A) and with solutions containing 1 μM flecainide (B), 1 μM
quinidine (C) and 10 μM quinidine (D). Hashing indicates hearts
demonstrating arrhythmic activity, and dots indicate hearts not
demonstrating such activity
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642 Pflugers Arch - Eur J Physiol (2008) 455:637–651nicity. The control plot obtained from WT hearts perfused
with control solution (six hearts, Fig. 3a, A) gave a
quadratic relationship between endocardial and epicardial
APD90 (solid line), in agreement with previous work [34].
Thus the curve y=ax
2+bx+c, where a=0.0097±0.0028,
b=1.46±0.27 and c=−5.06±6.34, gave a reduced χ
2 of
0.49. Repeating the regression analysis this time fitting the
line y = mx + c gave a reduced χ
2 of 0.86, and permitted the
derivation of an F statistic for the appropriate, N+1=17
data points, given by Fχ ¼ N
χ2
2 χ2
3
χ2
3

in which the sub-
scripts on the right-hand side of the equation denote the
number of parameters involved [5]. This yielded a
probability of exceeding F of <0.05, suggesting that
inclusion of the quadratic term was justified, again in full
agreement with the previous study [34].
Data points obtained under the range of genetic and
pharmacological conditions studied could then be compared
with this reference curve (broken lines, Fig. 3) with the
expectation that the departure of points to the left of this curve
might be associated with arrhythmogenicity [34]. However,
data sets obtained before and after the pharmacological
manoeuvres satisfied this expectation in WT but clearly
failed to do so in the remaining genetically modified hearts.
First, treatment of WT hearts (Fig. 3a) with flecainide
(five hearts, B), 1 μM quinidine (six hearts, C) and 10 μM
quinidine (six hearts, D) all resulted in points falling to the
left of the reference curve, in parallel with the occurrence
of arrhythmic activity under these conditions (Fig. 2a, B, C
and D). Secondly, data points obtained from Scn5a+/Δ
hearts (Fig. 3b) treated with control solution (five hearts, A)
again fell to the left of the reference curve in contrast with
the low incidence of arrhythmic activity in this setting
(Fig. 2b, A). This pattern was maintained when such hearts
were exposed to flecainide (five hearts, Fig. 3b, B), once
again in contrast with the low frequency which arrhythmic
activity was observed under these conditions (Fig. 2b, B).
Exposure to 1 μM quinidine (five hearts, Fig. 3b, C) and
10 μM quinidine (six hearts, D) again both resulted in
points falling to the left of the control curve, this time in
parallel with the high incidence of arrhythmic activity
in these settings (Figs. 2b, C and 3b, D). Thirdly, data
points obtained from Scn5a+/− hearts (Fig. 3c) treated with
control solution (six hearts, A) consistently fell on the
reference curve, in contrast with the occurrence of
arrhythmic activity in this setting (Fig. 2c, A). Furthermore,
treatment with flecainide (six hearts, Fig. 3c, B) failed to
result in a left-shift of data points, in contrast with the large
increase in the incidence of arrhythmic activity (Fig. 2c, B).
In addition, points obtained during treatment with either
1 μM quinidine (five hearts, Fig. 3c, C) or 10 μM quinidine
(seven hearts, D) again fell to the left of the reference curve,
in contrast with the anti-arrhythmic effect of this agent
demonstrated in Fig. 2c, C and D.
Alterations in the slopes of restitution curves correlate
with the presence and absence of arrhythmic activity
Restitution curves (data points, left ordinate) were then
plotted using the APD90 (left ordinate) and DI data obtained
during the dynamic pacing protocol from the epicardia
(circles, Fig. 4) and endocardia (squares, Fig. 5)o fW T
(Figs. 4a, 5a), Scn5a+/Δ (Figs. 4b, 5b) and Scn5a+/−
(Figs. 4c, 5c) hearts for the first time. Hearts were studied
during treatment with control solution (A) and with
solutions containing flecainide (B), 1 μM quinidine (C) or
10 μM quinidine (D). Under all conditions, epicardial and
endocardial APD90 both decreased as DI decreased.
Increases or decreases in the slopes of such relationships
were in full agreement with the presence or absence of
arrhythmic activity under all conditions studied.
Restitution curves yield parameters predictive
of arrhythmogenicity
To permit quantitative analysis, simple mono-exponential
growth functions, as used previously [28], were fitted to the
experimental data. These took the form:
y ¼ y0 þ A 1   e x=τ 
ð1Þ
where y represents APD90, x represents DI, and y0, A and τ
are constants obtained by least squares fitting to the
experimental values of APD90 and DI in each case. These
fitted parameters, along with corresponding reduced χ
2
values, are shown in Tables 1 (epicardium) and 2
(endocardium). Curve fits performed on data sets obtained
by separating successive odd- and even-numbered action
potentials yielded statistically indistinguishable (P>0.05)
parameters in all cases (Tables 3 and 4) thus eliminating the
possibility of error arising as a result of averaging. The
corresponding gradients were then given by:
dy
dx
¼
A
t
  e x=t ð2Þ
and take their largest values at the shortest BCLs studied.
Figures 4 and 5 thus superimpose optimisations of Eq. 1
to the data shown in Tables 1 and 2 (solid lines, left-hand
Fig. 3 Relationships between epicardial and endocardial action
potential durations (at 90% repolarization, APD90s) obtained over a
range of baseline cycle lengths. WT (a), Scn5a+/Δ (b) and Scn5a+/−
(c) hearts were exposed to control solution (A) and to solutions
containing 1 μM flecainide (B), 1 μM quinidine (C) and 10 μM
quinidine (D) and stimulated at baseline cycle lengths of between
80 ms and 175 ms. Broken lines indicate reference curves constructed
by least-squares fitting of the equation y=ax
2+bx+c to data points
obtained from wild-type hearts treated with control solution
R
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Fig. 4 Epicardial restitution curves plotting action potential dura-
tion (at 90% repolarization, APD90) against preceding diastolic
interval (DI). Data were obtained from the epicardia (circles)o fW T
(a), Scn5a+/Δ (b) and Scn5a+/− (c) hearts exposed to control
solution (A) and to solutions containing 1 μM flecainide (B), 1 μM
quinidine (C) and 10 μM quinidine (D). Curves are fitted with mono-
exponential growth functions obtained by least squares fitting to the
experimental values of APD90 and DI (solid lines, left ordinates).
Gradients were obtained by differentiation of the fitted functions
(broken lines, right axes). Shaded boxes indicate ranges of DI values
at which such gradients exceed unity
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Fig. 5 Endocardial restitution curves plotting action potential dura-
tion (at 90% repolarization, APD90) against preceding diastolic
interval (DI). Data were obtained from the endocardia (squares)o f
WT (a), Scn5a+/Δ (b) and Scn5a+/− (c) hearts exposed to control
solution (A) and to solutions containing 1 μM flecainide (B), 1 μM
quinidine (C) and 10 μM quinidine (D). Curves are fitted with mono-
exponential growth functions obtained by least squares fitting to the
experimental values of APD90 and DI (solid lines, left ordinates).
Gradients were obtained by differentiation of the fitted functions
(broken lines, right axes). Shaded boxes indicate ranges of DI values
at which such gradients exceed unity
Pflugers Arch - Eur J Physiol (2008) 455:637–651 645ordinates). Furthermore, they show the corresponding
gradients calculated using Eq. 2 (broken lines, right-hand
axes). Shaded regions where present indicate DIs less than
the critical DI at which these gradients exceed unity: the
existence of such a region is an established criterion for
arrhythmogenesis [25]. Critical DI was calculated as:
criticalDI ¼  t   ln
t
A

ð3Þ
Figure 6 proceeds to show these values of critical DI
derived from the fitted values of A and τ for the epicardia
(filled bars) and endocardia (open bars) under each of the
above conditions. In contrast to the findings from the
analysis of the relationships between epicardial and
endocardial APD90s described above, the present analysis
of epicardial and endocardial restitution properties together
provided datasets in complete agreement with the observed
incidences of arrhythmic activity.
First, in WT hearts (Fig. 6a) exposed to control solution
(A) the critical DI took a value of −63.63±14.41 ms in the
epicardium and −15.43±4.97 ms in the endocardium.
Treatment with flecainide (B) significantly (P<0.05)
increased these values to 19.45±9.39 ms in the epicardium
and58.75±18.71msintheendocardium.ThiscriticalDIwas
attained in the endocardium (shaded region in Fig. 5a, B), in
parallel with the increased incidence of arrhythmogenesis
observed during the extrasystolic stimulation procedure
under these conditions (Fig. 2, ii). Treatment with 1 μM
quinidine (Fig. 6a, C) also significantly (P<0.05) increased
the critical DI in both the epicardium and endocardium
(32.30±7.80 ms and 27.80±14.53 ms respectively) in
parallel with the observed arrhythmogenicity on extrasys-
tolic stimulation under these conditions (Fig. 2, ii), although
such values were not attained during the dynamic pacing
protocol. Furthermore, treatment with 10 μM quinidine
(Fig. 6a, D) again significantly (P<0.05) increased these
Table 1 Fit parameters for epicardial restitution curves
Condition y0 (ms) A (ms) τ (ms) χ
2
WT (6 hearts) 1.6±4.4 56.2±2.4 58.4±9.8 1.4
WT + flecainide (5 hearts) −16.3±9.4 104.7±7.1 82.8±28.0 5.9
WT+1 μM quinidine (6 hearts) −38.3±17.4 92.4±14.7 45.1±9.4 2.5
WT+10 μM quinidine (6 hearts) −863.0±1,387.1 981.6±1,369.1 27.1±15.9 113.3
Scn5a+/Δ (5 hearts) −19.6±7.2 90.0±4.4 53.1±10.7 14.0
Scn5a+/Δ + flecainide (5 hearts) −16.1±6.5 82.2±12.3 95.3±42.1 3.5
Scn5a+/Δ+1 μM quinidine (5 hearts) −677.1±306.1 748.0±304.7 15.2±2.2 10.0
Scn5a+/− (6 hearts) −674.8±329.9 729.4±329.1 14.2±2.1 8.4
Scn5a+/− + flecainide (6 hearts) −56,359.8±2,559.7 52,677.3±2.2 7.8±2.5 14.8
Scn5a+/−+1 μM quinidine (5 hearts) −118.3±57.4 202.5±49.4 36.4±10.5 16.7
Scn5a+/−+10 μM quinidine (7 hearts) −1.7±44.7 131.9±62.3 158.4±262.2 10.8
Results of least-squares fits to the function y ¼ y0 þ A 1   e x=C 
under the conditions indicated
Table 2 Fit parameters for endocardial restitution curves
Condition y0 (ms) A (ms) τ (ms) χ
2
WT (6 hearts) −11.8±3.7 73.8±1.7 65.2±8.4 1.2
WT + flecainide (5 hearts) −769.0±244.1 827.3±243.7 14.5±1.3 1.4
WT+1 μM quinidine (6 hearts) −65.8±100.4 113.5±98.3 24.9±12.0 11.7
WT+10 μM quinidine (6 hearts) −41.9±71.5 78.2±68.7 32.8±19.3 13.6
Scn5a+/Δ (5 hearts) −31.9±9.0 109.9±5.1 49.6±9.0 10.3
Scn5a+/Δ + flecainide (5 hearts) −561.1±1.2 631.6±15.1 18.7±0.3 6.7
Scn5a+/Δ+1 μM quinidine (5 hearts) −499.7±143.8 563.0±142.9 16.3±1.6 56.0
Scn5a+/− (6 hearts) −281.7±9.8 43.5±6.4 48.5±19.0 4.3
Scn5a+/− + flecainide (6 hearts) −1,050.6±1,558.5 1,100.1±1,557.8 11.7±4.0 10.0
Scn5a+/−+1 μM quinidine (5 hearts) −261.2±117.9 350.5±107.8 34.2±9.3 21.7
Scn5a+/−+10 μM quinidine (7 hearts) −220.1±322.0 319.1±316.8 26.2±12.7 45.5
Results of least-squares fits to the function y ¼ y0 þ A 1   e x=C 
under the conditions indicated
646 Pflugers Arch - Eur J Physiol (2008) 455:637–651Table 4 Fit parameters for endocardial restitution curves separating successive odd- and even-numbered action potentials
Condition Odd Even
y0 (ms) A (ms) τ (ms) χ
2 y0 (ms) A (ms) τ (ms) χ
2
WT (6 hearts) −17.4±5.3 73.8±2.8 67.3±
13.5
4.7 −38.9±15.4 91.6±13.0 46.5±8.5 1.8
WT + flecainide (5 hearts) −49.2±26.2 113.8±23.0 35.7±8.2 7.6 −367.3±171.3 426.9±170.6 17.7±2.4 1.3
WT+1 μM quinidine
(6 hearts)
−393.2±368.6 437.7±368.6 14.9±4.3 18.1 −1,337.3±1,206.4 1,384.5±1,205.7 11.5±2.5 14.7
WT+10 μM quinidine
(6 hearts)
−17.7+−39.0 53.2±35.0 42.6±
28.9
11.2 −28.0±62.7 66.6±58.2 39.6±
29.7
17.3
Scn5a+/Δ (5 hearts) −149.6±131.4 221.0±128.6 26.4±7.6 0.9 −42.3±10.5 115.3±8.2 40.8±5.0 2.6
Scn5a+/Δ + flecainide
(5 hearts)
−1,133.8±784.2 1,201.4±783.1 15.2±2.6 2.0 −2,164.0±1,195.7 2,233.3±1,195.0 13.6±1.6 1.4
Scn5a+/Δ+1μM quinidine
(5 hearts)
−2,720.4±
3,917.8
2,779.7±
3,917.2
10.4±2.8 3.4 −3,527.2±
4,674.78
3,603.0±4,674.1 11.1±2.7 3.9
Scn5a+/− (6 hearts) −134.6±28.9 195.3±28.0 22.8±2.1 3.3 −149.1±33.5 212.0±32.6 22.9±2.2 3.6
Scn5a+/− + flecainide
(6 hearts)
−13.8±29.2 66.2±27.1 32.5±
11.1
1.8 −55.4±55.5 108.6±54.6 23.6±5.9 1.2
Scn5a+/−+1 μM quinidine
(5 hearts)
−1,979.9±
1,709.0
2,051.5±
1,704.6
15.9±2.8 13.4 −108.4±15,101.8 10,911.4±
15,098.3
11.8±3.0 14.8
Scn5a+/−+10 μM
quinidine (7 hearts)
−332.1±447.2 431.4±439.8 25.2±
12.7
116.0 −160.0±289.5 262.2±281.9 20.1±
18.1
48.1
Results of least-squares fits to the function y ¼ y0 þ A 1   e x=C 
under the conditions indicated
Table 3 Fit parameters for endocardial restitution curves separating successive odd- and even-numbered action potentials
Condition Odd Even
y0 (ms) A (ms) τ (ms) χ
2 y0 (ms) A (ms) τ (ms) χ
2
WT (6 hearts) 13.4±7.6 40.5±12.9 50.3±21.4 6.3 8.1±11.2 58.3±25.4 48.2±32.3 4.6
WT + flecainide (5 hearts) −14.7±8.9 105.2±9.0 88.0±31.3 5.8 −44.6±18.5 117.4±14.2 49.0±9.9 1.5
WT+1 μM quinidine
(6 hearts)
−20.6±9.9 75.8±6.2 56.4±13.2 3.8 −34.2±11.7 89.2±9.3 45.9±7.8 3.3
WT+10 μM quinidine
(6 hearts)
−1,391.7±
3,195.9
1,496.0±
3,182.0
21.1±14.3 117.9 −393.1±5.3.0 532.8±481.7 41.1±27.6 115.7
Scn5a+/Δ (5 hearts) −23.9±8.3 92.0±5.3 47.8±9.0 12.4 −24.4±8.6 92.6±5.6 47.6±8.9 11.8
Scn5a+/Δ + flecainide
(5 hearts)
14.6±6.3 77.1±8.4 84.1±32.2 3.4 −33.2±46.4 110.1±41.9 36.4±13.1 2.0
Scn5a+/Δ+1 μM
quinidine (5 hearts)
−250.2±12.8 483.0±24.5 18.8±7.8 12.4 −254.7±321.2 328.1±318.3 20.0±7.7 5.3
Scn5a+/− (6 hearts) −850.4±282.7 904.2±282.1 13.5±1.3 4.3 −913.3±283.3 968.6±282.7 13.7±1.2 3.7
Scn5a+/− + flecainide
(6 hearts)
−1,473.8±
3,144.5
1,534.3±
2,141.2
14.7±7.6 34.3 −2,108.8±
4,489.9
2,171.3±
4,486.8
14.0±6.7 35.0
Scn5a+/−+1 μM
quinidine (5 hearts)
−46.8±51.2 146.8±21.3 59.5±43.5 9.4 −46.7±50.6 149.2±20.2 61.0±44.2 9.3
Scn5a+/−+10 μM
quinidine (7 hearts)
7.3±34.2 167.7±264.8 272.8±
78.3
10.8 2.8±44.6 143.1±121.3 192.2±
405.8
12.0
Results of least-squares fits to the function y ¼ y0 þ A 1   e x=C 
under the conditions indicated
Pflugers Arch - Eur J Physiol (2008) 455:637–651 647values to 97.20±57.90 ms in the epicardium and to 28.50±
34.52 ms in the endocardium. This DI was attained in the
epicardium in parallel with the observed arrhythmogenicity
during the extrasystolic stimulation procedure (Fig. 2, ii).
Thus, increases in the critical DI are precisely paralleled
with arrhythmogenicity in WT hearts treated with flecainide
and quinidine.
Secondly, critical DIs obtained from Scn5a+/Δ hearts
(Fig. 6b) were always significantly greater than those in
WT controls (P<0.05 in all cases) in parallel with the
increased incidence of arrhythmic activity observed during
the extrasystolic stimulation procedure (Fig. 2, ii). Thus, in
heartstreated with control solution (Fig. 6b, A) the critical DI
increased to 28.04±8.08 ms in the epicardium and 39.38±
10.28 ms in the endocardium: These values were attained in
both the epicardium and endocardium in association with
the increased incidence of arrhythmic activity on extra-
systolic stimulation observed (Fig. 2, ii) and in full
agreement with clinical expectations [23]. Treatment with
flecainide (Fig. 6b, B) decreased the epicardial value
(−14.09±9.05 ms, P<0.05 as compared to hearts treated
with control solution) but did not significantly affect the
endocardial value (21.41±8.58 ms, P>0.05 as compared to
hearts treated with control solution), having no effect on the
observed incidence of arrhythmic activity on extrasystolic
stimulation (Fig. 2, ii). However, treatment with 1 μM
quinidine (Fig. 6b, C) significantly (P<0.05) increased both
epicardial and endocardial values (59.09±26.91 ms and
57.64±16.68 ms, respectively) as compared to those
obtained from such hearts treated with control solution, in
association with the observed increases in the incidence of
arrhythmic activity resulting from extrasystolic stimulation
(Fig. 2, ii) and again in agreement with expectations from
clinical work [33]. It was not possible to obtain MAPs over
a sufficiently wide range of BCLs to permit the construction
of such curves in Scn5a+/Δ hearts treated with 10 μM
quinidine.
Thirdly,criticalDIvalueswerealsoincreasedinScn5a+/−
hearts (Fig. 6c) in association with the increased incidence
of arrhythmic activity observed. Thus, in hearts treated with
control solution (A), the critical DIs were significantly
(P<0.05) increased as compared to WT controls in both
the epicardium and endocardium to 56.00±27.79 ms and
52.59±9.50 ms, respectively. These values were attained
in both the epicardium and endocardium, fulfilling clinical
expectations [1]. Treatment with flecainide (B) did not
significantly alter these values (68.14±24.09 ms in the
epicardium and 58.56±14.75 ms in the endocardium).
These were again attained in both epicardium and endocar-
dium in association with the arrhythmic activity observed
on extrasystolic stimulation (Fig. 2, ii). Furthermore,
treatment with quinidine at a concentration of 1 μM
(Fig. 6c, C) had no significant effect on critical DIs in
either the epicardium or endocardium (62.45±29.74 ms and
79.63±39.31 ms, respectively). These values were again
attained in both epicardium and endocardium. However,
treatment with quinidine at 10 μM significantly decreased
both epicardial and endocardial critical DIs, such that they
became statistically indistinguishable from WT controls
(29.01±9.27 ms and −80±3.58 ms, respectively). This was
associated with the complete absence of arrhythmogenesis
during the extrasystolic stimulation procedure (Fig. 2,i i ) .
Thus, while relationships between epicardial and endo-
cardial action potential durations obtained over a range of
cycle lengths are poorly correlated with arrhythmogenicity,
restitution curves are, in general, predictive of arrhythmo-
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Fig. 6 Critical diastolic intervals
obtained from restitution curves.
Critical diastolic intervals at
which gradients equalled unity
obtained from epicardial (filled
bars) and endocardial (open
bars) restitution curves shown in
Figs. 4 and 5 in WT (a), Scn5a+/
Δ (b)a n dScn5a+/− (c) hearts
exposed to control solution (A)
and to solutions containing 1 μM
flecainide (B), 1 μM quinidine
(C)a n d1 0μM quinidine (D).
Asterisks indicate values that are
significantly (P<0.05) larger
than those recorded in WT hearts
exposed to control solution
648 Pflugers Arch - Eur J Physiol (2008) 455:637–651genicity under the genetic and pharmacological conditions
studied.
Discussion
The congenital LQT3 and the BrS constitute two important
examples of genetic causes for ventricular arrhythmia and
sudden cardiac death [3]. These conditions result from
similarly targeted mutations in the SCN5a gene coding for
the cardiac Na
+ channel: gain-of-function mutations are
characteristic of LQT3, while loss-of-function mutations are
characteristic of BrS [1, 23].
The present study began by using the MAP technique to
verify that Langendorff-perfused murine hearts modelling
LQT3 (Scn5a+/Δ)[ 13] and BrS (Scn5a+/−)[ 29] recapit-
ulated features of the incidence of arrhythmic activity
reported clinically. These results were in full agreement
with previous physiological and pharmacological findings
from our LQT3 [39] and BrS [38] models. Epicardial and
endocardial MAP recordings were then used to evaluate the
applicability of two established criteria in predicting
arrhythmogenicity in these models over the full physiolog-
ical range of heart rates (quantified as baseline cycle
lengths, BCLs).
Transmural dispersion of repolarization was studied over
a range of BCLs by comparing epicardial and endocardial
action potential durations (at 90% repolarization, APD90s)
in the two genetic models. Such an analysis had previously
been demonstrated to reveal arrhythmogenicity in hypoka-
laemic Langendorff-perfused murine hearts [34]. Further-
more, changes in this relationship investigated at a single
BCL had previously been associated with arrhythmogenic-
ity in our Scn5a+/Δ hearts [42]. Plots of epicardial against
endocardial APD90 in WT hearts treated with control
solution gave reference relationships best fitted by a
quadratic function, in full agreement with previous work
[34]. Treatment of such WT hearts with either quinidine or
flecainide resulted in the data points falling to the left of the
reference curves, reflecting increased transmural repolari-
zation gradients, in association with increased incidences of
arrhythmic activity and again in full agreement with a
previous study [34]. However, such plots failed to
consistently predict the presence or absence of arrhythmo-
genicity in the Scn5a+/Δ and Scn5a+/− hearts. Such left-
shifting of points was observed in Scn5a+/Δ hearts under
all pharmacological conditions studied, despite the estab-
lished anti-arrhythmic effect of flecainide in this setting.
Furthermore, data points obtained from Scn5a+/− hearts
treated with control solution fell on the reference curve
despite the increased incidence of arrhythmic activity
observed. Treatment with flecainide failed to result in a
left-shift of points, despite its established pro-arrhythmic
effect; treatment with quinidine did result in such a shift,
despite its anti-arrhythmic effect.
These discrepancies prompted an investigation for
alternative criteria for arrhythmogenicity. We therefore
explored the applicability of a second approach involving
restitution curves plotting APD90 against the preceding DI.
Arrhythmic activity occurring in a range of settings has
previously been associated with increases in the slopes of
such curves to greater than unity [14, 17–19, 28, 40]. Such
an association has been demonstrated in a canine pharma-
cological model of the congenital long QT syndrome type 2
[45] but has not previously been studied in any models of
LQT3 or BrS in any species. Furthermore, decreases in the
slopes of such curves have been associated with the effects
of clinically important anti-arrhythmic drugs, including the
class 1A agent procainamide in a canine model [32].
However, such slopes have not been examined in relation to
either quinidine or flecainide, nor have any such studies
previously been attempted in murine models. This study
accordingly proceeded to construct epicardial and endocar-
dial restitution curves for the first time in a murine system
and in relation to LQT3 or BrS in any species.
In contrast to the previous criterion, epicardial and
endocardial restitution curves taken together yielded
parameters in precise agreement with the presence or
absence of arrhythmic phenomena demonstrated. In WT
hearts, treatment with either quinidine or flecainide signif-
icantly increased the critical DI at which the slopes of the
restitution curves exceeded unity, in full agreement with the
increased incidences of arrhythmic activity observed. Not
only did the Scn5a+/Δ and Scn5a+/− mutations result in
significant increases in critical DI in association with
increased rates of arrhythmic activity, but quinidine and
flecainide exerted contrasting effects on this critical DI in
agreement with clinical expectations in both cases. Thus, in
Scn5a+/Δ hearts, treatment with quinidine increased
critical DIs in association with its pro-arrhythmic effect.
Furthermore, in Scn5a+/− hearts, treatment with quinidine
decreased critical DIs in association with the decreased
incidence of arrhythmic activity observed, while treatment
with flecainide had the opposite effect. Thus class 1A
agents may result in either increases (quinidine in WT
and Scn5a+/Δ murine hearts) or decreases (quinidine in
Scn5a+/− murine hearts and procainamide in canine hearts)
[32] in the critical DI: Such changes are in full agreement
with effects on arrhythmogenicity in all cases.
Taken together, these results demonstrate that criteria
considering effects on the slopes of restitution curves
successfully account for arrhythmogenicity in murine
models of arrhythmic syndromes resulting from mutations
in the Scn5a Na
+ channel, as well as for the effects of
quinidine and flecainide on such arrhythmogenicity. These
observations might form the basis for future clinical
Pflugers Arch - Eur J Physiol (2008) 455:637–651 649explorations of the utility of restitution curves obtained
using the MAP technique [28, 40] in the assessment of
arrhythmic propensity in hereditary arrhythmic syndromes.
Such a robust means of assessing arrhythmogenicity might
be particularly useful given the known variable expressivity
of the arrhythmic phenotype in patients harbouring such
mutations [41].
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